186 related articles for article (PubMed ID: 20824046)
1. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice.
Ren Y; Fleischmann D; Foygel K; Molvin L; Lutz AM; Koong AC; Jeffrey RB; Tian L; Willmann JK
Invest Radiol; 2012 Jan; 47(1):25-32. PubMed ID: 22178893
[TBL] [Abstract][Full Text] [Related]
3. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
5. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
[TBL] [Abstract][Full Text] [Related]
8. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Wachsberger P; Burd R; Ryan A; Daskalakis C; Dicker AP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):854-61. PubMed ID: 19801101
[TBL] [Abstract][Full Text] [Related]
9. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
10. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Siemann DW; Norris CM; Ryan A; Shi W
Anticancer Res; 2009 Jun; 29(6):1987-92. PubMed ID: 19528456
[TBL] [Abstract][Full Text] [Related]
11. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
13. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility and comparison of DCE-MRI and DCE-CT perfusion parameters in a rat tumor model.
Ng CS; Waterton JC; Kundra V; Brammer D; Ravoori M; Han L; Wei W; Klumpp S; Johnson VE; Jackson EF
Technol Cancer Res Treat; 2012 Jun; 11(3):279-88. PubMed ID: 22417064
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
[TBL] [Abstract][Full Text] [Related]
16. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
17. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
18. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
Cesca M; Frapolli R; Berndt A; Scarlato V; Richter P; Kosmehl H; D'Incalci M; Ryan AJ; Giavazzi R
Neoplasia; 2009 Nov; 11(11):1155-64. PubMed ID: 19881951
[TBL] [Abstract][Full Text] [Related]
19. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.
Bhattacharya A; Turowski SG; San Martin ID; Rajput A; Rustum YM; Hoffman RM; Seshadri M
Anticancer Res; 2011 Feb; 31(2):387-93. PubMed ID: 21378316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
